Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus [6]

JAMA

Volumn 298, Issue 3, 2007, Pages 285-

  Ross, Lainie Friedman ^a   Philipson, Louis H ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAZIL; FOLLOW UP; HEALTH PROMOTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; METHODOLOGY; PEDIATRICS; POPULATION; PRIORITY JOURNAL; RESEARCH ETHICS;

EID: 34447559702     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.3.285-a     Document Type: Letter

References (5)

1. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568-1576.
2. World Medical Association Declaration of Helsinki. World Medical Association Web site. http://www.wma.net/e/policy/b3.htm. Published October 9, 2004. Accessed April 11, 2007.
3. Knip M, Sakkinen A, Huttunen NP, et al. Postinitial remission in diabetic children: an analysis of 178 cases. Acta Paediatr Scand. 1982;71(6):901-908.
4. Yilmaz MT, Devrim AS, Biyal F, et al. Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results. Diabetes Res Clin Pract. 1993;19(2):151-162.
5. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988; 318(11):663-670.